CDSCO drug alert: Himachal pulls 92 substandard batches, halts 96 pharma units

Himachal Pradesh’s Drugs Control Administration warned patients and the public to stop using specified medicine batches declared “not of standard quality” by CDSCO. The alert covered 92 samples made in the state. Seventy failed critical efficacy tests, while 22 had minor defects such as labelling problems.

The flagged medicines included Namik-MR tablets, AX Cold syrup, Healtuss LS, Cufcott LS, K-Coff-D syrup, and Gone Gel. Their failures involved active ingredients such as aceclofenac, ambroxol hydrochloride, levosalbutamol, phenylephrine hydrochloride, and methyl salicylate. The problems could affect how well the products work.

The state also ordered 96 pharmaceutical facilities to halt manufacturing, either completely or in specific sections. Officials stressed that these actions were not all linked to the latest NSQ list. Some followed inspections that found other deficiencies, and corrective steps or legal action were required.

“Not of standard quality” means a medicine does not meet a required specification set by regulators. The failure may involve its active-ingredient amount, dissolution performance, or another quality requirement. This matters because a product can look normal yet deliver too little medicine or fail to release it properly.

For example, Namik-MR tablets failed an aceclofenac assay, while several syrups failed tests for ambroxol hydrochloride or other ingredients. These products were identified as NSQ because testing found a quality failure. The article does not describe them as counterfeit, and it does not report deliberate imitation.

A counterfeit medicine is different. It is deliberately misrepresented, such as a product carrying a false identity, composition, or manufacturer. NSQ status concerns failure to meet specifications, whether caused during production or later affected by distribution conditions. The article specifically notes that storage, heat, humidity, and transport can contribute to quality failure.

Himachal Pradesh is a major pharmaceutical hub. The state accounts for about 35% of India’s domestic drug formulations, and officials describe this as roughly every third drug on a chemist’s shelf. It also exports large volumes. More than 650 manufacturing units operate there, mainly around Baddi.

The September 2026 CDSCO report flagged 330 drug samples nationwide. Ninety-two came from Himachal Pradesh. State authorities said 70 of those failed assay or dissolution tests, while 22 had minor defects, including labelling problems. These figures show the scale of both production and scrutiny.

The state ordered 96 facilities to stop manufacturing entirely or in specific sections. Officials clarified that these 96 actions were part of an ongoing process. Some involved NSQs, while others followed inspections that found separate deficiencies. The state’s share of failed samples fell from 34% in July to 28% in September.

Assay and dissolution tests examine two essential parts of medicine performance. An assay measures how much active ingredient is present. Dissolution checks how the medicine releases that ingredient under test conditions. Regulators focus on them because a medicine must contain the intended amount and make it available in a usable form.

In the Himachal Pradesh findings, 70 of 92 samples failed critical efficacy parameters, specifically assay and dissolution tests. Namik-MR failed its aceclofenac content test. AX Cold failed its ambroxol hydrochloride level, while Healtuss LS and Cufcott LS failed tests involving ambroxol hydrochloride and levosalbutamol.

A failed assay may indicate too little or too much active ingredient. A failed dissolution test may indicate that the ingredient is not released as required. Either problem can reduce treatment reliability. The article also records minor defects, such as labelling issues, which are different from these critical efficacy failures.

A medicine works as intended only when it contains the right amount of active ingredient and releases it properly. If either condition fails, the patient may receive less effective treatment than expected. This is why regulators classify assay and dissolution failures as critical efficacy problems.

The article gives several examples. Namik-MR failed its aceclofenac content test. AX Cold failed its ambroxol hydrochloride level. Healtuss LS and Cufcott LS failed tests for ambroxol hydrochloride and levosalbutamol. These were medicines used for pain, cough, congestion, or breathing-related symptoms.

The immediate concern is reduced treatment reliability. Symptoms may not improve as expected because the body receives too little active ingredient or does not receive it in the intended way. The article does not report specific patient injuries from these batches. It does report that authorities asked patients and the public to stop using the specified products and batches.

The 96 facilities were stopped because regulators found quality or compliance concerns. Some actions followed NSQ findings. Others followed inspections that identified different deficiencies. Manufacturing was halted either across an entire facility or only in particular sections while corrective action was pending.

CDSCO provides the national testing and reporting layer. Its September 2026 report flagged 330 samples, including 92 from Himachal Pradesh. The state Drugs Control Administration then acted within Himachal Pradesh. It can suspend or cancel manufacturing licences, stop production, and work with authorities where samples were collected for testing.

The state also said legal action may be taken in the jurisdictions from which samples were drawn. This creates a wider enforcement chain rather than a single response. Officials described the process as ongoing administrative check-and-balance. They also said increased detection may indicate that regulatory systems are becoming stronger.

Medicine quality can change during distribution. The state drug controller identified storage conditions, temperature, humidity, and rough transport as stress factors. These conditions can affect a product between factory release and use by a patient. The problem may therefore arise after manufacturing, during movement or storage.

For example, a batch might face excessive heat in transit or high humidity in a storage location. Repeated rough handling could add further stress. The article does not identify one specific batch as damaged by these conditions, but it explains that such factors can cause quality failure. They are separate from a confirmed manufacturing defect.

This complicates enforcement. Regulators must examine both manufacturers and the distribution chain rather than automatically blaming the factory. The state still applies a zero-tolerance approach and takes action when standards are not met. Better controls across storage and transport could help preserve medicine quality before products reach patients.